topiramate
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Vascular Headaches
Conditions
Vascular Headaches, Migraine
Trial Timeline
Oct 1, 2000 → Dec 1, 2001
NCT ID
NCT00253175About topiramate
topiramate is a phase 3 stage product being developed by Johnson & Johnson for Vascular Headaches. The current trial status is completed. This product is registered under clinical trial identifier NCT00253175. Target conditions include Vascular Headaches, Migraine.
What happened to similar drugs?
20 of 20 similar drugs in Vascular Headaches were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00223626 | Phase 2 | Completed |
| NCT00266604 | Approved | Completed |
| NCT00223639 | Phase 2 | Completed |
| NCT00233012 | Phase 1 | Completed |
| NCT00210574 | Phase 2 | Completed |
| NCT00210860 | Phase 3 | Completed |
| NCT00210925 | Phase 2 | Completed |
| NCT00231647 | Phase 2 | Completed |
| NCT00210821 | Phase 3 | Completed |
| NCT00210873 | Phase 3 | Completed |
| NCT00210808 | Phase 2/3 | Completed |
| NCT00210912 | Phase 3 | Completed |
| NCT00236496 | Phase 3 | Completed |
| NCT00035230 | Phase 3 | Completed |
| NCT00231673 | Phase 2 | Completed |
| NCT00231634 | Phase 3 | Terminated |
| NCT00231621 | Phase 3 | Terminated |
| NCT00231595 | Phase 3 | Completed |
| NCT00236665 | Phase 3 | Completed |
| NCT00236509 | Phase 3 | Completed |
Competing Products
20 competing products in Vascular Headaches